• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'.

作者信息

Rosenbaum James Todd, Weisman Michael H, Shafer Cassie, Aslanyan Elin, Howard Richard A, Ogle Kimberly, Hamilton Hedley, Reveille John D, Winthrop Kevin L, Choi Dongseok

机构信息

Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA

Legacy Devers Eye Institute, Portland, Oregon, USA.

出版信息

Ann Rheum Dis. 2023 Jun;82(6):e138. doi: 10.1136/annrheumdis-2021-220588. Epub 2021 May 13.

DOI:10.1136/annrheumdis-2021-220588
PMID:33985940
Abstract
摘要

相似文献

1
Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'.关于“风湿性疾病患者中与COVID-19相关死亡的相关因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信
Ann Rheum Dis. 2023 Jun;82(6):e138. doi: 10.1136/annrheumdis-2021-220588. Epub 2021 May 13.
2
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases.关于吉安弗兰切斯科所著《风湿性疾病患者新冠病毒肺炎住院相关特征：来自新冠病毒肺炎全球风湿病联盟医生报告登记处的数据》的通信。在风湿性肌肉骨骼疾病患者中，疾病活动度而非糖皮质激素治疗，可能与新冠病毒肺炎的严重程度相关。
Ann Rheum Dis. 2022 Nov;81(11):e222. doi: 10.1136/annrheumdis-2020-218845. Epub 2020 Sep 7.
3
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M by Andreica and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin .COVID-19全球风湿病联盟注册研究、抗白细胞介素-6治疗、共同决策与患者预后。对以下文章的回应：吉安弗朗切斯科撰写的“风湿病患者COVID-19住院相关特征：来自COVID-19全球风湿病联盟医生报告注册研究的数据”；汗撰写的“在临床试验出现之前，在严重COVID-19伴高炎症中同情使用托珠单抗——一家地区综合医院的真实世界经验”；安德烈伊卡撰写的“对吉安弗朗切斯科·M撰写的‘风湿病患者COVID-19住院相关特征：来自COVID-19全球风湿病联盟医生报告注册研究的数据’的评论”；安萨林撰写的“接受免疫调节药物治疗的系统性自身免疫疾病患者的COVID-19结局” 。
Ann Rheum Dis. 2022 Oct;81(10):e191. doi: 10.1136/annrheumdis-2020-218713. Epub 2020 Aug 12.
4
Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'.关于“风湿性疾病患者中与COVID-19相关死亡的因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信
Ann Rheum Dis. 2023 May;82(5):e115. doi: 10.1136/annrheumdis-2021-220099. Epub 2021 Mar 1.
5
Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'.关于“风湿性疾病患者中与COVID-19相关死亡的因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信
Ann Rheum Dis. 2023 May;82(5):e113. doi: 10.1136/annrheumdis-2021-220037. Epub 2021 Feb 18.
6
Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers.对阿诺德和德维利耶斯的《关于“风湿性疾病患者中与COVID-19相关死亡的因素：COVID-19全球风湿病联盟医生报告登记处的结果”的通信》的回复
Ann Rheum Dis. 2023 May;82(5):e114. doi: 10.1136/annrheumdis-2021-220058. Epub 2021 Feb 18.
7
Correspondence to: 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco .致信：吉安弗兰切斯科所著的《风湿病患者中与 COVID-19 住院相关的特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据》
Ann Rheum Dis. 2023 Jun;82(6):e140. doi: 10.1136/annrheumdis-2020-218733. Epub 2020 Aug 19.
8
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo .风湿性疾病活动、糖皮质激素使用与2019冠状病毒病。对以下内容的回应：“关于‘风湿性疾病患者2019冠状病毒病住院相关特征：来自2019冠状病毒病全球风湿病联盟医生报告登记处的数据’的通信”，作者为詹弗兰切斯科。乔洛指出：“在风湿性肌肉骨骼疾病患者中，疾病活动而非糖皮质激素治疗可能与2019冠状病毒病的严重程度相关。”
Ann Rheum Dis. 2022 Nov;81(11):e223. doi: 10.1136/annrheumdis-2020-218910. Epub 2020 Sep 7.
9
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者 COVID-19 相关死亡的相关因素：来自 COVID-19 全球风湿病联盟医生报告登记处的结果。
Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.
10
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience.关于吉安弗兰切斯科的《风湿性疾病患者新冠病毒肺炎住院相关特征：来自新冠病毒肺炎全球风湿病联盟医生报告登记处的数据》的通信。在临床试验出现之前，托珠单抗在伴有高度炎症的重症新冠病毒肺炎中的同情用药——一家地区综合医院的真实世界经验。
Ann Rheum Dis. 2022 Oct;81(10):e188. doi: 10.1136/annrheumdis-2020-218528. Epub 2020 Jul 30.

引用本文的文献

1
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series.冠状病毒病（COVID-19）大流行期间皮下注射英夫利昔单抗（CT-P13 SC）治疗强直性脊柱炎患者的真实世界证据：病例系列
Clin Case Rep. 2022 Jan 13;10(1):e05233. doi: 10.1002/ccr3.5233. eCollection 2022 Jan.